

Information For the User
Obeticholic acid (5mg)

Obewise 5

Obewise 5 Tablet

Composition:

Each tablet contains:

- Obeticholic Acid – 5 mg

Description:

Obewise 5 Tablet contains Obeticholic Acid, a farnesoid X receptor (FXR) agonist used in the treatment of primary biliary cholangitis (PBC), a chronic liver disease that affects the bile ducts. It works by regulating bile acid metabolism and reducing liver inflammation and fibrosis progression.

Pharmacological Action:

Obeticholic Acid activates FXR, a key regulator of bile acid homeostasis, reducing bile acid synthesis and accumulation in hepatocytes. This mechanism helps decrease liver inflammation and cholestatic injury.

Indications:

- Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) or as monotherapy in patients intolerant to UDCA.

Dosage & Administration:

- Recommended starting dose: 5 mg once daily.
- May be increased to 10 mg daily based on patient response and tolerance.
- Taken orally with or without food.

Contraindications:

- Complete biliary obstruction.
- Severe hepatic impairment without dose adjustments.
- Hypersensitivity to Obeticholic Acid or any excipients.

Warnings & Precautions:

- Monitor liver function tests regularly, as it may cause hepatotoxicity.
- Patients with severe pruritus may require dose adjustments or symptomatic treatment.
- Use caution in patients with decompensated cirrhosis.

Adverse Effects:

- Pruritus, fatigue, abdominal pain
- Increased liver enzymes
- Nausea, diarrhea, or constipation

Drug Interactions:

- Bile acid sequestrants may reduce the absorption of Obeticholic Acid and should be administered separately.
- Monitor when used with CYP3A4 inhibitors, as they may affect drug metabolism.

Storage Conditions:

- Store in a cool, dry place below 25°C.
- Keep out of reach of children.

Conclusion:

Obewise 5 Tablet is an effective treatment for primary biliary cholangitis, offering liver-protective benefits by regulating bile acid metabolism. Regular monitoring is recommended to optimize therapy and minimize potential side effects.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for